Association between the CYP1A2 rs762551 Polymorphism and Bladder Cancer Susceptibility: a Meta-Analysis Based on Case-Control Studies

  • Zeng, Yong (Department of Cardiothoracic Surgery, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University) ;
  • Jiang, Hua-Yong (Department of Radiation Oncology, Beijing Military General Hospital) ;
  • Wei, Li (Department of Oncology, the 401 hospital of PLA) ;
  • Xu, Wei-Dong (Department of Radiation Oncology, Beijing Military General Hospital) ;
  • Wang, Ya-Jie (Department of Oncology, Changhai Hospital, Second Military Medical University) ;
  • Wang, Ya-Di (Department of Radiation Oncology, Beijing Military General Hospital) ;
  • Liu, Chuan (Department of Oncology, Changhai Hospital, Second Military Medical University)
  • Published : 2015.11.04


Background: Previous studies evaluated associations between the CYP1A2 rs762551 polymorphism and bladder cancer risk. However, the results were inconsistent. We therefore performed a meta-analysis of the published case-control studies to assess in detail the association between CYP1A2 rs762551 polymorphism and bladder cancer risk. Materials and Methods: PubMed, Embase and Web of Science were searched to identify relevant studies and the pooled odds ratio (OR) and 95 % confidence interval (95%CI) were calculated. Results: A total of seven articles including 3,013 cases and 2,771 controls were finally included. Overall, a significant association was found between the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for CC vs AA (OR=0.82, 95% CI=0.69~0.99), but no significant associations were found for the other three models (AC vs AA: OR=0.91, 95% CI=0.81~1.02; the dominant model: OR=0.90, 95% CI=0.80~1.00; the recessive model: OR=0.84, 95% CI =0.72~1.00). In the subgroup analysis by ethnicity, we detected significant associations between the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for GA vs GG (OR = 0.78, 95% CI =0.64~0.96) and for the recessive model (OR=0.80, 95% CI=0.66~0.96) in Caucasians, but not for Asians. Conclusions: The results from the meta-analysis suggested that the CYP1A2 rs762551 polymorphism is a protective factor for bladder cancer, especially in Caucasians.


Meta-analysis;CYP1A2 rs762551;bladder cancer;susceptibility;ethnicity


  1. Altayli E, Gunes S, Yilmaz AF, Goktas S, Bek Y (2009). CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population. Int Urol Nephrol, 41, 259-66.
  2. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50, 1088-101.
  3. Bozina N, Bradamante V, Lovric M (2009). Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol, 60, 217-42
  4. Butler MA, Lang NP, Young JF, et al (1992). Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics, 2, 116-27.
  5. Chung WG, Kang JH, Park CS, Cho MH, Cha YN (2000). Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: determination by caffeine metabolism. Clin Pharmacol Ther, 67, 258-66.
  6. Caporaso N, Landi MT, Vineis P (1991). Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics, 1, 4-19
  7. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
  8. Cui X, Lu X, Hiura M, et al (2013). Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population. Environ Health Prev Med, 18, 136-42.
  9. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88
  10. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in metaanalysis detected by a simple graphical test. BMJ, 315, 629-34.
  11. Figueroa JD, Malats N, Garcia-Closas M, et al (2008). Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis, 29, 1955-62.
  12. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  13. Ioannidis JP, Boffetta P, Little J, et al (2008). Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol, 37, 120-32.
  14. Kiemeney LA, Grotenhuis AJ, Vermeulen SH, Wu X (2009). Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol, 19, 540-6.
  15. Kiltie AE (2010). Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev, 20, 218-24.
  16. Li D, Jiao L, Li Y, et al (2006). Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, and risk of pancreatic cancer. Carcinogenesis, 27, 103-11.
  17. Mandal RK, Dubey S, Panda AK, Mittal RD (2014). Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis. Tumour Biol, 35, 6415-23
  18. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48
  19. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol, 37, 136-46.
  20. Miranda CL, Yang YH, Henderson MC, et al (2000). Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNAexpressed human CYP1A2. Drug Metab Dispos, 28, 1297-302.
  21. Nordmark A, Lundgren S, Cnattingius S, Rane A (1999). Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol, 47, 397-402.
  22. Pavanello S, Simioli P, Lupi S, Gregorio P, Clonfero E (2002). Exposure levels and cytochrome P450 1A2 activity, but not N-acetyltransferase, glutathione S-transferase (GST) M1 and T1, influence urinary mutagen excretion in smokers. Cancer Epidemiol Biomarkers Prev, 11, 998-1003.
  23. Pavanello S, Mastrangelo G, Placidi D, et al (2010). CYP1A2 polymorphisms, occupational and environmental exposures and risk of bladder cancer. Eur J Epidemiol, 25, 491-500.
  24. Qiu LX, Yao L, Mao C, Yu KD, Zhan P, et al (2010). Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: A meta-analysis involving 17,600 subjects. Breast Cancer Res Treat, 122, 521-5.
  25. Rodriguez-Antona C, Ingelman-Sundberg M (2006). Cytochrome P450 pharmacogenetics and cancer. Oncogene, 25, 1679-91.
  26. Sachse C, Bhambra U, Smith G, et al (2003). Colorectal Cancer Study Group. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol, 55, 68-76.
  27. Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol, 47, 445-9.
  28. Sangrajrang S, Sato Y, Sakamoto H, et al (2009). Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer, 125, 837-43.
  29. Sesardic D, Boobis AR, Edwards RJ, Davies DS (1988). A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the odeethylation of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol, 26, 363-72.
  30. Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29.
  31. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies inmeta-analyses. Eur J Epidemiol, 25, 603-5.
  32. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR (2000). Empirical assessment of effect of publication bias on metaanalysis. BMJ, 320, 1574-7.
  33. Tsukino H, Kuroda Y, Nakao H, et al (2004). Cytochrome P450 (CYP) 1A2, sulfotransferase (SULT) 1A1, and N-acetyltransferase (NAT) 2 polymorphisms and susceptibility to urothelial cancer. J Cancer Res Clin Oncol, 130, 99-106.
  34. Villanueva CM, Silverman DT, Murta-Nascimento C, et al (2009). Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control, 20, 121-7.
  35. Volanis D, Kadiyska T, Galanis A, et al (2010). Environmental factors and genetic susceptibility promote urinary bladder cancer. Toxicol Lett, 193, 131-7.
  36. Wang Y, Kong CZ, Zhang Z, Yang CM, Li J (2014). Relationships between CYP1A1 genetic polymorphisms and bladder cancer risk: a meta-analysis. DNA Cell Biol, 33, 171-81.
  37. Xiong T, Yang J, Wang H, et al (2014). The association between the Lys751Gln polymorphism in the XPD gene and the risk of bladder cancer. Mol Biol Rep, 41, 2629-34.